Sutro Biopharma (STRO) Short-term Investments (2018 - 2026)

Sutro Biopharma has reported Short-term Investments for 8 years, with the latest figure at $83.3 million in Q4 2025.

• Quarterly Short-term Investments fell 34.2% year-over-year to $83.3 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $83.3 million (down 34.2% YoY) and the FY2025 annual result came in at $83.3 million, down 34.2% from the prior year.
• Short-term Investments slipped to $83.3 million in Q4 2025 per STRO's latest filing, from $101.7 million in the prior quarter.
• Over five years, Short-term Investments peaked at $284.8 million in Q2 2024 and troughed at $33.3 million in Q2 2023.
• A 5-year average of $134.0 million and a median of $135.7 million in 2021 frame the typical range for Short-term Investments.
• The sharpest annual moves came in 2023 and 2024: Short-term Investments slumped 83.56% in 2023, then jumped 753.94% in 2024.
• Over 5 years, Short-term Investments stood at $130.3 million in 2021, then soared by 95.71% to $255.1 million in 2022, then plunged by 83.56% to $41.9 million in 2023, then soared by 201.86% to $126.6 million in 2024, then slumped by 34.2% to $83.3 million in 2025.
• According to Business Quant data, Short-term Investments over the past three periods registered $83.3 million, $101.7 million, and $141.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.